Santacruzamate A is a highly potent and selective histone deactylase 2 (HDAC2) inhibitor (IC50 = 112 - 119 pM). Also inhibits HDAC6 in nanomolar range (IC50 = 433 nM). Displays >3500 fold selectivity for HDAC2 over HDAC6, and >8500-fold selectivity over HDAC4 (IC50 >1 μM for HDAC4). Inhibits growth of HuT-78 cutaneous T-cell lymphoma cell line. Identified as targeting human host proteins that interact with SARS-CoV-2.
Caractéristiques techniques
| Marque | Tocris Bioscience |
|---|
| Réf. B-LABO | BL-RE-125919 |
|---|
| Réf. fabricant | 18757166 |
|---|
| Nom chimique ou matériau | Ethyl N-[4-oxo-4-[(2-phenylethyl)amino]butyl]carbamate |
|---|
| CAS | 1477949-42-0 |
|---|
| Quantité | 50 mg |
|---|
| Cible | Class II Histone Deacetylases Inhibitors |
|---|
| Formule moléculaire | C<sub>15</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub> |
|---|
| Pureté | 0.98 |
|---|
Une question, une configuration particulière ?
Contactez-nous pour un devis.
